tetano
Editor, Senior Moderator
Clin Infect Dis. 2019 Sep 27. pii: ciz927. doi: 10.1093/cid/ciz927. [Epub ahead of print] [h=1]Hemagglutinin-stalk antibody responses following trivalent inactivated influenza vaccine immunization of pregnant women and association with protection from influenza virus illness.[/h]
Dhar N[SUP]1,[/SUP][SUP]2[/SUP], Kwatra G[SUP]1,[/SUP][SUP]2[/SUP], Nunes MC[SUP]1,[/SUP][SUP]2[/SUP], Cutland C[SUP]1,[/SUP][SUP]2[/SUP], Izu A[SUP]1,[/SUP][SUP]2[/SUP], Nachbagauer R[SUP]3[/SUP], Krammer F[SUP]3[/SUP], Madhi SA[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h] 1 Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2 Department of Science and Technology, National Research Foundation, Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The conserved, immuno-subdominant influenza virus hemagglutinin (HA) stalk region is a potential universal group-specific influenza virus vaccine epitope. We analysed antibody responses to H1 hemagglutinin stalk-domain (H1/stalk) following trivalent influenza inactivated vaccine (IIV3) vaccination in pregnant women, and association with protection against influenza virus illness.
[h=4]METHODS:[/h] One-hundred and forty-five HIV-uninfected (68 IIV3 and 77 placebo-recipients) and 140 HIV-infected (72 IIV3 and 68 placebo-recipients) pregnant women were independently randomised in placebo-controlled efficacy trials of IIV3. Plasma samples were tested for H1/stalkIgG and hemagglutination-inhibition (HAI) antibodies pre-vaccination and one-month post-vaccination. Women had weekly surveillance for influenza illness, confirmed by polymerase chain reaction.
[h=4]FINDINGS:[/h] Increases in H1/stalk IgG (and HAI) antibody levels were elicited post-IIV3; with responses being higher in HIV-uninfected than HIV-infected women. Among HIV-uninfected vaccinees, there was no correlation (post-vaccination) between H1/stalk and HAI antibody responses, whereas a strong correlation was observed in HIV-infected vaccinees. The H1/stalk IgG concentration was lower among women developing A/H1N1-illness (85.3 arbitrary units (AU)/ml) than those without A/H1N1-illness (219.6 AU/ml; p=0.001). H1/stalk IgG concentration ≥215 AU/ml was associated with 90% lower odds (odds ratio=0.09; p=0.005) of A/H1N1-illness. Also, H1/stalk IgG were significantly lower among women with influenza B-illness (93.9 AU/ml) than their counter-parts (215.5 AU/ml; p=0.04), however, no association was observed after adjusting for HAI titers.
[h=4]CONCLUSIONS:[/h] H1/stalk IgG concentration was associated with lower odds for A/H1N1 influenza virus illness, indicating its potential as an epitope for a universal vaccine against Group-1 influenza virus.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
[h=4]KEYWORDS:[/h] Influenza; immunization; pregnant; protection; stalk antibody
PMID: 31565750 DOI: 10.1093/cid/ciz927
Dhar N[SUP]1,[/SUP][SUP]2[/SUP], Kwatra G[SUP]1,[/SUP][SUP]2[/SUP], Nunes MC[SUP]1,[/SUP][SUP]2[/SUP], Cutland C[SUP]1,[/SUP][SUP]2[/SUP], Izu A[SUP]1,[/SUP][SUP]2[/SUP], Nachbagauer R[SUP]3[/SUP], Krammer F[SUP]3[/SUP], Madhi SA[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h] 1 Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2 Department of Science and Technology, National Research Foundation, Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The conserved, immuno-subdominant influenza virus hemagglutinin (HA) stalk region is a potential universal group-specific influenza virus vaccine epitope. We analysed antibody responses to H1 hemagglutinin stalk-domain (H1/stalk) following trivalent influenza inactivated vaccine (IIV3) vaccination in pregnant women, and association with protection against influenza virus illness.
[h=4]METHODS:[/h] One-hundred and forty-five HIV-uninfected (68 IIV3 and 77 placebo-recipients) and 140 HIV-infected (72 IIV3 and 68 placebo-recipients) pregnant women were independently randomised in placebo-controlled efficacy trials of IIV3. Plasma samples were tested for H1/stalkIgG and hemagglutination-inhibition (HAI) antibodies pre-vaccination and one-month post-vaccination. Women had weekly surveillance for influenza illness, confirmed by polymerase chain reaction.
[h=4]FINDINGS:[/h] Increases in H1/stalk IgG (and HAI) antibody levels were elicited post-IIV3; with responses being higher in HIV-uninfected than HIV-infected women. Among HIV-uninfected vaccinees, there was no correlation (post-vaccination) between H1/stalk and HAI antibody responses, whereas a strong correlation was observed in HIV-infected vaccinees. The H1/stalk IgG concentration was lower among women developing A/H1N1-illness (85.3 arbitrary units (AU)/ml) than those without A/H1N1-illness (219.6 AU/ml; p=0.001). H1/stalk IgG concentration ≥215 AU/ml was associated with 90% lower odds (odds ratio=0.09; p=0.005) of A/H1N1-illness. Also, H1/stalk IgG were significantly lower among women with influenza B-illness (93.9 AU/ml) than their counter-parts (215.5 AU/ml; p=0.04), however, no association was observed after adjusting for HAI titers.
[h=4]CONCLUSIONS:[/h] H1/stalk IgG concentration was associated with lower odds for A/H1N1 influenza virus illness, indicating its potential as an epitope for a universal vaccine against Group-1 influenza virus.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
[h=4]KEYWORDS:[/h] Influenza; immunization; pregnant; protection; stalk antibody
PMID: 31565750 DOI: 10.1093/cid/ciz927